REGENERON PHARMACEUTICALS, INC. (REGN)
Pharmaceutical Preparations
Latest Price
$793.74
TTM P/E
19.66
Normalized P/E
19.29
Div Yield
0.35%
Book Value
306.69
P/B Ratio
2.59
Valuation metrics
adjust assumptions →EPS: $41.48
Book value / share: $287.82
Formula: √(22.5 × EPS × BVPS)
Graham Number
$518.29
35% downside
Norm. op. income: $4.0B (median of 7yr)
Tax rate: 11%
Discount rate: 10%
Growth assumption: zero (EPV is a no-growth value)
Earnings Power Value
$389.06
51% downside
Base FCF: $4.1B (median of recent 5yr)
Growth: -3%/yr (median YOY, capped at 25%)
Discount rate: 10%
Terminal growth: 3%
Projection horizon: 10 years
DCF Fair Value
$428.04
46% downside
EPS: $41.48
Target P/E: 19×
Formula: EPS × P/E
P/E Fair Value
$788.12
1% downside
Institutional Ownership
89.8% held by institutions| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| BlackRock, Inc. | 9.11M | $5.68B | 8.87% | +165.8K | 2026-06-30 |
| VANGUARD CAPITAL MANAGEMENT LLC | 6.63M | $4.13B | 6.45% | -25.2K | 2026-06-30 |
| Dodge & Cox | 4.87M | $3.04B | 4.74% | +412.9K | 2026-06-30 |
| STATE STREET CORP | 4.83M | $3.01B | 4.70% | +170.2K | 2026-06-30 |
| Invesco Ltd. | 3.94M | $2.46B | 3.83% | +2.22M | 2026-06-30 |
| JPMORGAN CHASE & CO | 3.77M | $2.38B | 3.67% | -166.0K | 2026-06-30 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 3.18M | $1.98B | 3.09% | +1.45M | 2026-06-30 |
| FRANKLIN RESOURCES INC | 2.77M | $1.73B | 2.70% | +49.8K | 2026-06-30 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.63M | $1.63B | 2.55% | +18.1K | 2026-06-30 |
| Nuveen, LLC | 2.02M | $1.26B | 1.96% | -45.1K | 2026-06-30 |